14,339 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Precision Wealth Strategies LLC

Precision Wealth Strategies LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,339 shares of the company’s stock, valued at approximately $793,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 4,277,218 shares of the company’s stock worth $206,846,000 after acquiring an additional 57,181 shares during the last quarter. BVF Inc. IL increased its stake in Protagonist Therapeutics by 35.5% in the 1st quarter. BVF Inc. IL now owns 2,575,015 shares of the company’s stock worth $124,528,000 after purchasing an additional 675,000 shares in the last quarter. Wellington Management Group LLP raised its holdings in Protagonist Therapeutics by 5.0% during the 1st quarter. Wellington Management Group LLP now owns 987,370 shares of the company’s stock worth $47,749,000 after buying an additional 47,293 shares during the period. Woodline Partners LP raised its holdings in Protagonist Therapeutics by 54.2% during the 1st quarter. Woodline Partners LP now owns 897,699 shares of the company’s stock worth $43,413,000 after buying an additional 315,372 shares during the period. Finally, Invesco Ltd. lifted its stake in Protagonist Therapeutics by 16.3% during the first quarter. Invesco Ltd. now owns 859,648 shares of the company’s stock valued at $41,573,000 after buying an additional 120,696 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Buying and Selling

In other news, Director William D. Waddill sold 4,000 shares of the firm’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $64.25, for a total transaction of $257,000.00. Following the transaction, the director owned 5,130 shares in the company, valued at approximately $329,602.50. This trade represents a 43.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 22,065 shares of Protagonist Therapeutics stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $55.05, for a total transaction of $1,214,678.25. Following the completion of the sale, the chief executive officer directly owned 548,538 shares of the company’s stock, valued at approximately $30,197,016.90. The trade was a 3.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 70,859 shares of company stock worth $3,944,577 in the last 90 days. 4.90% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Trading Down 3.7%

NASDAQ PTGX opened at $64.00 on Thursday. Protagonist Therapeutics, Inc. has a 1-year low of $33.31 and a 1-year high of $68.26. The firm’s fifty day simple moving average is $58.15 and its 200-day simple moving average is $52.31. The company has a market capitalization of $3.98 billion, a PE ratio of 91.43 and a beta of 2.20.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, August 6th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The firm had revenue of $5.55 million during the quarter, compared to analysts’ expectations of $8.32 million. As a group, analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

PTGX has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, June 8th. Leerink Partnrs upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research report on Friday, September 12th. Barclays started coverage on Protagonist Therapeutics in a report on Wednesday, September 17th. They issued an “overweight” rating and a $72.00 target price for the company. Citigroup reiterated an “outperform” rating on shares of Protagonist Therapeutics in a report on Thursday, August 7th. Finally, JMP Securities upped their price target on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $68.36.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.